Invivyd, INC

Invivyd, Inc. received a deficiency letter from Nasdaq for failing to meet the minimum $1.00 bid price requirement for its common stock.

Invivyd, Inc. announced it has received a twelve-month advanced notice of termination for the Emergency Use Authorization (EUA) of its COVID-19 monoclonal antibody, PEMGARDA, from the U.S. FDA, effective June 29, 2027.

Invivyd, Inc. announced the results of its Annual Meeting of Stockholders held on May 19, 2026, including the election of directors and ratification of PricewaterhouseCoopers LLP as its independent auditor.

Invivyd announced first quarter 2026 financial results, highlighting a 22% year-over-year increase in PEMGARDA net product revenue to $13.7 million, while advancing its VYD2311 clinical programs.

Invivyd announced progress in its COVID-19 program with a slight delay in Phase 3 results and the advancement of a novel measles monoclonal antibody candidate, VMS063.

Invivyd, Inc. announced robust fourth-quarter and full-year 2025 financial results, highlighted by significant PEMGARDA revenue growth and rapid advancement of its pivotal VYD2311 clinical trial.

Invivyd, Inc. filed its Q1 2026 10-Q report, detailing a net loss of $41.4 million and continued investment in its VYD2311 COVID-19 program.

Invivyd, a biopharmaceutical company, reported significantly reduced net losses and increased product revenue in Q3 2025, while advancing its VYD2311 COVID-19 prevention program with positive FDA feedback.

Invivyd, Inc. reported a significantly reduced net loss in the second quarter of 2025, driven by increased PEMGARDA sales, while advancing its next-generation COVID-19 antibody, VYD2311, towards potential BLA approval.

Invivyd, Inc. reports its first quarter 2025 financial results, including $11.3 million in product revenue, but expresses substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows.

Invivyd, Inc. reported its third quarter 2024 financial results, highlighting revenue from PEMGARDA sales and progress in clinical development of its next-generation antibody candidate.

Invivyd, Inc. reports its first product revenue following emergency use authorization for PEMGARDA, while also disclosing substantial doubt about its ability to continue as a going concern.

Invivyd, Inc. reports increased PEMGARDA sales and significant clinical progress for VYD2311 in 2025, yet faces substantial doubt about its ability to continue as a going concern due to recurring losses.

Invivyd's 10-K filing highlights the company's focus on commercializing PEMGARDA and advancing VYD2311, while navigating financial uncertainties and regulatory landscapes.

Invivyd, Inc.'s 10-K filing outlines the company's common stock details, regulatory environment, and recent emergency use authorization for PEMGARDA.

Invivyd, Inc. reports that Director Ajay Royan acquired 50,000 stock options with an exercise price of $1.04.

Invivyd, Inc. director Kevin F. McLaughlin acquired 50,000 stock options with an exercise price of $1.04, vesting in full by May 19, 2027.

Invivyd, Inc. reports that Director Terrance McGuire was granted 50,000 stock options with an exercise price of $1.04.

Invivyd, Inc. reports the grant of 50,000 stock options to Marc Elia, a director and other significant stakeholder, with a potential vesting date in May 2027.

Invivyd, Inc. reports that Director Paul Bolno acquired stock options, indicating a potential long-term commitment to the company.

Invivyd, Inc. director Tamsin Berry has acquired 50,000 stock options with an exercise price of $1.04, vesting in full by May 2027.

Invivyd, Inc. has issued its proxy statement detailing the upcoming 2026 Annual Meeting of Stockholders, scheduled for May 19, 2026, to elect directors and ratify auditor appointments.

Invivyd, Inc. announces its 2025 Annual Meeting of Stockholders to be held on May 20, 2025, and provides details on how stockholders can vote on key proposals.

Invivyd, Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on May 20, 2025, featuring proposals for director elections and ratification of the company's independent accounting firm.

Invivyd, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on May 21, 2024, to elect directors and ratify the appointment of PricewaterhouseCoopers LLP as the company's independent accounting firm.

Adimab, LLC has reported a decrease in its beneficial ownership of Invivyd, Inc. common stock to 7.3% following recent open market sales.

Adimab, LLC has reduced its beneficial ownership in Invivyd, Inc. to 8.8% after selling over 1.2 million shares in open market transactions.

Mithril Capital Management's beneficial ownership in INVIVYD, INC. decreased to 4.8% due to dilution from the issuer's recent share sales.

Polaris Partners and affiliated entities report a decrease in their aggregate beneficial ownership of INVIVYD, INC. common stock to 3.0% following the issuer's recent share sales.

M28 Capital Management LP and Marc Elia have filed an exit amendment to their Schedule 13D for Invivyd, Inc., indicating their beneficial ownership has fallen below 5% due to an increase in outstanding shares.

RA Capital Management and its affiliates report a 7% beneficial ownership stake in Invivyd, Inc. through pre-funded warrants.

Maverick Capital, Ltd. and its affiliates have filed an amended Schedule 13G, reporting a 6.7% beneficial ownership stake in Invivyd, Inc. as of December 31, 2025.

Soleus Capital Management and affiliated entities report a combined 2.8% passive beneficial ownership in Invivyd, Inc. common stock.

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have disclosed a 7.9% beneficial ownership stake in INVIVYD, INC., totaling 21,785,166 shares.

Point72 Asset Management, L.P. and affiliates have disclosed a 9.7% beneficial ownership stake in Invivyd, Inc., totaling over 20 million shares.

Janus Henderson Group plc and its affiliates have reported a 12.1% beneficial ownership stake in INVIVYD, INC. common stock, held for investment purposes.